In-hospital safety in field conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. B. Gambiense Sleeping Sickness

Hdl Handle:
http://hdl.handle.net/10144/272002
Title:
In-hospital safety in field conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. B. Gambiense Sleeping Sickness
Authors:
Schmid, C; Kuemmerle, A; Blum, J; Ghabri, S; Kande, V; Mutombo, W; Ilunga, M; Lumpungu, I; Mutanda, S; Nganzobo, P; Tete, D; Mubwa, N; Kisala, M; Blesson, S; Mordt, O V
Journal:
PLoS Neglected Tropical Diseases
Abstract:
Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.
Affiliation:
Department of Medicines Research, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Issue Date:
29-Nov-2012
URI:
http://hdl.handle.net/10144/272002
DOI:
10.1371/journal.pntd.0001920
PubMed ID:
23209861
Language:
en
ISSN:
1935-2735
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorSchmid, Cen_GB
dc.contributor.authorKuemmerle, Aen_GB
dc.contributor.authorBlum, Jen_GB
dc.contributor.authorGhabri, Sen_GB
dc.contributor.authorKande, Ven_GB
dc.contributor.authorMutombo, Wen_GB
dc.contributor.authorIlunga, Men_GB
dc.contributor.authorLumpungu, Ien_GB
dc.contributor.authorMutanda, Sen_GB
dc.contributor.authorNganzobo, Pen_GB
dc.contributor.authorTete, Den_GB
dc.contributor.authorMubwa, Nen_GB
dc.contributor.authorKisala, Men_GB
dc.contributor.authorBlesson, Sen_GB
dc.contributor.authorMordt, O Ven_GB
dc.date.accessioned2013-03-13T12:20:12Z-
dc.date.available2013-03-13T12:20:12Z-
dc.date.issued2012-11-29-
dc.identifier.citationIn-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. 2012, 6 (11):e1920 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735-
dc.identifier.pmid23209861-
dc.identifier.doi10.1371/journal.pntd.0001920-
dc.identifier.urihttp://hdl.handle.net/10144/272002-
dc.description.abstractTrypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseases and Open Accessen_GB
dc.titleIn-hospital safety in field conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. B. Gambiense Sleeping Sicknessen
dc.contributor.departmentDepartment of Medicines Research, Swiss Tropical and Public Health Institute, Basel, Switzerland.en_GB
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.